Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban-Reference-Cited by-同舟云学术

Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban

Published:2017-09 Issue:9 Volume:106 Page:2524-2534
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Tsuruya Yuri,Nakanishi Takeo,Komori Hisakazu,Wang Xinying,Ishiguro Naoki,Kito Tomoko,Ikukawa Kouji,Kishimoto Wataru,Ito Sumito,Schaefer Olaf,Ebner Thomas,Yamamura Norio,Kusuhara Hiroyuki,Tamai Ikumi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference44 articles.

1. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines;Ageno;Chest,2012

2. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines;Garcia;Chest,2012

3. Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly;Ogbonna;Drugs & Aging,2013

4. Xarelto™ (Rivaroxaban) Tablets,2011

5. Eliquis™ (Apixaban) Tablets,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers;Clinical Pharmacokinetics;2024-02-23

2. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: Application to prospective simulation of complex drug–drug interaction with rivaroxaban;British Journal of Clinical Pharmacology;2023-02-07

3. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents;Drug Metabolism and Pharmacokinetics;2021-06

4. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies;Clinical Pharmacokinetics;2020-02-13

5. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban;Drug Metabolism and Disposition;2019-09-10